Table 2.
Treatment outcome based on leukemia cell subtype and minimal residual disease in bone marrow at Day 15 of induction
| Number of patients (%) | 5-year EFS, % (95% CI) | 5-year CRR, % (95% CI) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRD <0.01% |
MRD 0.01% to<1% | MRD ≥1% |
MRD <0.01% |
MRD 0.01% to<1% |
MRD ≥1% |
P-value | MRD <0.01% |
MRD 0.01% to<1% |
MRD ≥1% |
P-value | |
| ETV6-RUNX1 | 68 (53.5) | 52 (40.9) | 7 (5.51) | 98.5 (95.0–100) |
98.1 (93.8–100) |
100 (100–100) |
0.92 | 0 | 1.9 (0.0–5.7) |
0 | 0.49 |
| High-hyperdiploid | 47 (30.9) | 68 (44.7) | 37 (24.3) | 100 (100–100) |
96.3 (90.8–100) |
87.9 (76.1–99.7) |
0.05 | 0 | 3.7 (0.0–8.9) |
6.4 (0.0–15.2) |
0.33 |
| DUX4-rearranged | 0 (0.00) | 10 (50.0) | 10 (50.0) | ---- | 90.0 (68.8–100) |
100 (100–100) |
0.32 | ---- | 0 | 0 | ---- |
| TCF3-PBX1 | 4 (25.0) | 7 (43.8) | 5 (31.3) | 100 (100–100) |
100 (100–100) |
60.0 (22.8–97.2) |
0.21 | 0 | 0 | 0 | 0.16 |
| PAX5alt | 6 (26.1) | 8 (34.8) | 9 (39.1) | 83.3 (44.9–100) |
75.0 (42.1–100) |
88.9 (68.3–100) |
0.75 | 16.7 (0.0–49.3) |
25.0 (0.0–57.3) |
11.1 (0.0–32.9) |
0.75 |
| T Cell | 23 (24.7) | 29 (31.2) | 41 (44.1) | 87.0 (70.5–100) |
89.1 (76.8–100) |
75.4 (61.1–89.7) |
0.30 | 4.3 (0.0–12.9) |
6.9 (0.0–16.3) |
17.2 (5.4–29.0) |
0.35 |
| ETP | 0 (0.00) | 3 (33.3) | 6 (66.7) | ---- | 100 (100–100) |
83.3 (50.0–100) |
0.48 | --- | 0 | 16.7 (0.0–49.3) |
0.48 |
| iAMP21 | 1 (20.0) | 1 (20.0) | 3 (60.0) | 0 | 100 (100–100) |
100 (100–100) |
0.14 | ---- | 0 | 0 | 0.14 |
| Hypodiploid | 0 (0.00) | 4 (66.7) | 2 (33.3) | ---- | 100 (100–100) |
100 (100–100) |
0.26 | ---- | 0 | 0 | ---- |
| BCR-ABL1 | 1 (7.69) | 1 (7.69) | 11 (84.6) | 100 (100–100) |
100 (100–100) |
71.6 (43.4–99.8) |
0.52 | 0 | 0 | 19.3 (0.0–44.9) |
0.56 |
| BCR-ABL1-like | 3 (20.0) | 5 (33.3) | 7 (46.7) | 66.7 (23.2–100) |
80.0 (39.4–100) |
71.4 (34.0–100) |
0.87 | 0 | 20.0 (0.0–59.2) |
0 | 0.46 |
| ETV6-RUNX1-like | 2 (22.2) | 3 (33.3) | 4 (44.4) | 100 (100–100) |
33.3 (0.0–70.9) |
75.0 (32.5–100) |
0.38 | 0 | 33.3 (0.0–100) |
25.0 (0.0–74.0) |
0.66 |
| KMT2A-rearranged | 6 (21.4) | 11 (39.3) | 11 (39.3) | 66.7 (29.1–100) |
72.7 (44.5–100) |
54.5 (22.4–86.6) |
0.60 | 16.7 (0.0–49.3) |
27.3 (0.0–55.0) |
27.3 (0.0–55.2) |
0.94 |
| MEF2D-rearranged | 1 (33.3) | 1 (33.3) | 1 (33.3) | ---- | ---- | 0 | 0.37 | ---- | ---- | ---- | 0.37 |
| ZNF384-rearranged | 0 (0.00) | 0 (0.00) | 7 (100) | ---- | ---- | 100 (100–100) |
---- | ---- | ---- | 0 | ---- |
| NUTM1-rearranged | 3 (100) | 0 (0.00) | 0 (0.00) | 100 (100–100) |
---- | ---- | ---- | 0 | ---- | ---- | ---- |
| PAX5 P80R | 1 (50.0) | 1 (50.0) | 0 (0.00) | 100 (100–100) |
100 (100–100) |
---- | ---- | 0 | 0 | ---- | ---- |
| B-other | 21 (35.6) | 22 (37.3) | 16 (27.1) | 100 (100–100)) |
95.5 (86.1–100) |
62.5 (40.0–85.0) |
<0.001 | 0 | 0 | 31.3 (7.6–54.9) |
0.10 |
| Total | 187 (31.7) | 226 (38.3) | 177 (30.0) | 95.1 (91.2–99.0) |
92.5 (88.6–96.4) |
79.0 (72.3–85.7) |
<.001 | 2.2 (0.1–4.4) |
5.6 (2.5–8.7) |
13.5 (8.3–18.7) |
<.001 |
Abbreviation: MRD, minimal residual disease; No, number of patients; EFS, event-free survival; CCR, cumulative risk of any relapse; CI, confidence interval;
ETP, early T-cell precursor ALL.